From: Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
Demographic | Anti-VEGF | Sirolimus | ||
---|---|---|---|---|
N = 20 | N = 20 | |||
Mean | SD | Mean | SD | |
Age at baseline (years) | 79.24 | 8.86 | 84.46 | 5.76 |
Time with Wet AMD (months) | 76.95 | 55.83 | 54.20 | 40.43 |
Total previous intravitreal anti-VEGF injections | 36.95 | 21.87 | 29.45 | 22.03 |
Baseline visual acuity (ETDRS letters) | 53.90 | 12.87 | 47.10 | 16.29 |
Baseline central subfield thickness (µm) | 426.90 | 115.84 | 492.80 | 131.14 |
Baseline choroidal neovascularization (mm2) | 4.23 | 3.22 | 6.55 | 4.43 |
Baseline central macular thickness (µm) | 362.04 | 176.21 | 392.26 | 200.50 |